Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 23 h ago

Korsana Biosciences, Inc.: TCG Crossover GP II, LLC discloses a stake of more than 5% (Schedule 13G)

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 17 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

TCG Crossover GP II, LLC disclosed a stake exceeding 5% in Korsana Biosciences, Inc. via a Schedule 13G filing with the SEC (accession 0001193125-26-464095). The passive-investor disclosure signals a meaningful ownership position in the biotech, though the filing did not specify the exact share count or percentage held. A Schedule 13G is typically filed by investors who hold more than 5% but do not seek control, distinguishing it from activist 13D filings. The stake makes TCG Crossover a notable holder whose future buying or selling could draw attention. Investors will watch for an amended 13G or 13D if the position changes materially, and for any accompanying commentary on Korsana's pipeline or strategy.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

TCG Crossover GP II, LLC, Korsana Biosciences, Inc.